Workshop 18
Antiviral therapy and resistance 2

Programme

• 11:00 – 11:15 12 Min. 3 Min.

  • Abstract talk
  • O 106

  Characterization of Mpox virus genomes and patient isolates from Franconia (Bavaria, Germany) and antiviral testing of patient isolates

  • Dr. Arne Cordsmeier (Erlangen / DE)

   Antiviral therapy and resistance
• 11:15 – 11:30 12 Min. 3 Min.

  • Abstract talk
  • O 107

  Discovery and pre-clinical development of a novel class of host-directed pan-flavivirus therapeutics: A tale of two Orthoflavivirus – Zika and dengue viruses

  • Professor François Jean (Vancouver / CA)

   Antiviral therapy and resistance
• 11:30 – 11:45 12 Min. 3 Min.

  • Abstract talk
  • O 108

  NRF2 activators inhibit hepatitis E virus propagation in vitro

  • Fenja Laue (Hannover / DE)

   Antiviral therapy and resistance
• 11:45 – 12:00 12 Min. 3 Min.

  • Abstract talk
  • O 109

  Targeting HIV reservoir cells: Enhanced precision for in vivo gene delivery through bispecific AAV vectors

  • Samuel Theuerkauf (Langen / DE)

   Antiviral therapy and resistance
• 12:00 – 12:15 12 Min. 3 Min.

  • Abstract talk
  • O 110

  Geno2pheno-bNAbs: Interpretable and accurate prediction of HIV bNAb resistance

  • Dr. Martin Pirkl (Cologne / DE)

   Antiviral therapy and resistance
• 12:15 – 12:30 12 Min. 3 Min.

  • Abstract talk
  • O 111

  Helicase-primase inhibitor pritelivir for the treatment of resistant HSV infections in immunocompromised patients

  • Dr. Alexander Birkmann (Wuppertal / DE)

   Antiviral therapy and resistance